Glucerna in a Hospital Setting Beneficial to Type 2 Patients


By: Daniel Trecroci

In hospitalized people with type 2 diabetes, Glucerna was found to have a “neutral effect on [blood glucose] control and lipid metabolism . . . compared with a high-carbohydrate and a lower-fat formula.”

A research group from Madrid, Spain, compared blood glucose and lipid control in 63 hospitalized patients with type 2 diabetes requiring feeding via nasogastric tube. For an average of 13 days, the patients received a diet that was low in carbohydrate and high in monounsaturated fat (Glucerna) or a high-carbohydrate diet (Precitene Diabet).

“Mean glucose was significantly increased at seven days of treatment in the Precitene arm,” write the researchers, “with no significant variations in the Glucerna arm.”

In addition, average weekly blood triglyceride levels in the Precitene group were increased without reaching statistical significance, whereas patients in the Glucerna group showed a stable trend.

—Journal of Parenteral and Enteral Nutrition, January–February 2005



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.